4003.0: Tuesday, November 14, 2000: 8:30 AM-10:00 AM | ||||
| ||||
| Little is known about the effects of regulatory surveillance on prescribing quality. Although benzodiazepines (BZ) are generally safe and widely used in treating anxiety, insomnia, seizure disorders, and other conditions, they may present a danger for habituation, abuse, and injury. In 1989, New York added BZ to an existing Triplicate Prescription Program (TPP) for controlled substances, which is intended to reduce BZ diversion and inappropriate prescribing without affecting legitimate medical use. Although previous poorly-controlled studies found substantial reductions in BZ prescribing, as well as increases in undesireable substitutes, they did not assess access to or appropriateness of prescribing, either in aggregate or within vulnerable demographic and clinical groups, such as the elderly, minorities, schizophrenics and epileptics. Using appropriate quasi-experimental methods, this analysis examines the impact of TPP on access to BZ after program implementation, as well as appropriateness of BZ prescribing and use of potential substitute drugs, across the entire New York Medicaid population, as well as by risk groups | ||||
| See individual abstracts for presenting author's disclosure statement. | ||||
| Learning Objectives: Refer to the individual abstracts for learning objectives | ||||
| Linda Simoni-Wastila, PhD | ||||
| Stephen Soumerai, ScD | ||||
| Impact of physician monitoring on appropriateness of benzodiazepine prescribing in a Medicaid population Dennis Ross-Degnan, ScD, Linda Simoni-Wastila, PhD, Xiaoming Gao, Jeffrey Brown, MA, Connie Mah, MA, Leon Cosler, PhD, Thomas Fanning, PhD, Peter Gallagher, Carl Salzman, MD, Richard Platt, MD, Tom Inui, MD, Stephen Soumerai, ScD | ||||
| Impact of physician monitoring on appropriateness of BZ prescribing in Medicaid risk groups Linda Simoni-Wastila, PhD, Dennis Ross-Degnan, ScD, Xiaoming Gao, Jeffrey Brown, MA, Connie Mah, Leon Cosler, PhD, Thomas Fanning, Peter Gallagher, Carl Salzman, MD, Richard Platt, MD, Tom Inui, MD, Stephen Soumerai, ScD | ||||
| Overview of the New York triplicate prescription program and its impact on benzodiazepine utilization and prescribing appropriateness Stephen Soumerai, ScD, Dennis Ross-Degnan, ScD, Linda Simoni-Wastila, PhD, Xiaoming Gao, Jeffrey Brown, MA, Connie Mah, Leon Cosler, PhD, Thomas Fanning, Peter Gallagher, Carl Salzman, MD, Richard Platt, MD, Tom Inui, MD | ||||
| Discussion | ||||
| Sponsor: | Alcohol, Tobacco, and Other Drugs | |||
| Cosponsors: | Medical Care; Mental Health | |||